Biofil Chemicals & Pharmaceuticals Limited
Biofil Chemicals and Pharmaceuticals Limited engages in manufacturing and trading of pharmaceuticals in India. It operates through Pharmaceutical and Chemical divisions. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and … Read more
Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) - Total Assets
Latest total assets as of September 2025: ₹553.64 Million INR
Based on the latest financial reports, Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) holds total assets worth ₹553.64 Million INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biofil Chemicals & Pharmaceuticals Limited - Total Assets Trend (2008–2025)
This chart illustrates how Biofil Chemicals & Pharmaceuticals Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biofil Chemicals & Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Biofil Chemicals & Pharmaceuticals Limited's total assets of ₹553.64 Million consist of 83.5% current assets and 16.5% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹1.32 Million | 0.3% |
| Accounts Receivable | ₹383.15 Million | 75.2% |
| Inventory | ₹33.41 Million | 6.6% |
| Property, Plant & Equipment | ₹83.45 Million | 16.4% |
| Intangible Assets | ₹0.00 | 0.0% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Biofil Chemicals & Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biofil Chemicals & Pharmaceuticals Limited's current assets represent 83.5% of total assets in 2025, an increase from 10.2% in 2008.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2025, down from 0.8% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 75.2% of total assets.
Biofil Chemicals & Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Biofil Chemicals & Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Biofil Chemicals & Pharmaceuticals Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Biofil Chemicals & Pharmaceuticals Limited generates 0.66x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Biofil Chemicals & Pharmaceuticals Limited generates $ 1.09 in net profit.
Biofil Chemicals & Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.44 | 1.44 | 1.33 |
| Quick Ratio | 1.33 | 1.15 | 1.27 |
| Cash Ratio | 0.01 | 0.01 | 0.00 |
| Working Capital | ₹146.90 Million | ₹ 103.25 Million | ₹ 60.13 Million |
Biofil Chemicals & Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Biofil Chemicals & Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.74 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 8.2% |
| Total Assets | ₹509.60 Million |
| Market Capitalization | $2.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biofil Chemicals & Pharmaceuticals Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Biofil Chemicals & Pharmaceuticals Limited's assets grew by 8.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Biofil Chemicals & Pharmaceuticals Limited (2008–2025)
The table below shows the annual total assets of Biofil Chemicals & Pharmaceuticals Limited from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹509.60 Million | +8.24% |
| 2024-03-31 | ₹470.83 Million | +49.92% |
| 2023-03-31 | ₹314.06 Million | +67.66% |
| 2022-03-31 | ₹187.32 Million | -43.64% |
| 2021-03-31 | ₹332.38 Million | -21.54% |
| 2020-03-31 | ₹423.65 Million | +74.97% |
| 2019-03-31 | ₹242.13 Million | +0.24% |
| 2018-03-31 | ₹241.55 Million | +10.60% |
| 2017-03-31 | ₹218.40 Million | -9.50% |
| 2016-03-31 | ₹241.32 Million | +75.42% |
| 2015-03-31 | ₹137.56 Million | -5.77% |
| 2014-03-31 | ₹145.99 Million | +8.19% |
| 2013-03-31 | ₹134.93 Million | -4.36% |
| 2012-03-31 | ₹141.09 Million | +35.91% |
| 2011-03-31 | ₹103.81 Million | +1.26% |
| 2010-03-31 | ₹102.52 Million | +22.09% |
| 2009-03-31 | ₹83.97 Million | -10.47% |
| 2008-03-31 | ₹93.79 Million | -- |